Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval

Reuters
2024-12-06

By Foo Yun Chee

BRUSSELS, Dec 6 (Reuters) - Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.

Novo Holdings, the controlling shareholder of Danish drugmaker Novo Nordisk , which makes the blockbuster weight-loss drug Wegovy, had announced the deal in February.

"The proposed merger would not raise competition concerns on any of the markets examined in the EEA (European Economic Area) or on any substantial part of it," the European Commission said in a statement, confirming a Reuters story.

The EEA refers to the 27 EU countries, Iceland, Liechtenstein and Norway.

The EU antitrust watchdog said there are sufficient competing alternatives in the market.

Soaring sales of Wegovy have made Novo Nordisk Europe's most valuable company by market value.

(Reporting by Foo Yun Chee, additional reporting by Ludwig Burger in Frankfurt;)

((foo.yunchee@thomsonreuters.com; +32 2 585 2866; Reuters Messaging: foo.yunchee.thomsonreuters.com@reuters.net))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

no data

没有相关数据

如果下载按钮点击无跳转,请点击右上角菜单选择 “在浏览器打开”